CGEM Cullinan Therapeutics, Inc.
USHealthcareAs of 2026-08-24
Why CGEM matters now
Cullinan Therapeutics, Inc. (CGEM) is a US stock in Healthcare. The latest InvestLog snapshot shows $21.82 with +0.65% on the session and $1.34B in market capitalization; recent performance reads 1-month +5.99% and YTD +45.22%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-49.7M, and EPS of $-0.84. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -19.3%.
The latest indexable market news headline is "Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $30.00; recent insider activity includes Doyle Mittie filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.43
P/S
0.00
EV/EBITDA
-3.86
DCF Value
$1.44
FCF Yield
-19.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-51.5%
ROA
-54.9%
ROIC
-65.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-49.7M | $-0.84 |
| Q4 2025 | $0.00 | $-50.7M | $-0.86 |
| FY 2025 | $0.00 | $-219.9M | $-3.72 |
| Q3 2025 | $0.00 | $-50.6M | $-0.86 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$31.00
Target (Median)
$30.00
Target Range
$28.00 - $37.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Country
US
Exchange
—
Beta
0.01
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.